Grants.gov · AMRAA · Cooperative Agreement

DoW Breast Cancer, Breakthrough Award Level 4

Defense Health Agency Contracting Activity - DHACA

Status
Open
Maximum funding
Varies
Deadline
Sep 30, 2026
Instrument
Cooperative Agreement

About this funding opportunity

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 4.

Distinctive Features:

· Clinical trials are required.

· The research team must include two or more breast cancer consumer advocates.

· This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Topic areas: General and Cross-cutting R&D, Life Sciences and Health.

Funding amount

This cooperative agreement provides Varies in funding.

Deadline

Applications are due Sep 30, 2026. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

  • Open to all applicant types

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

DoW Breast Cancer, Breakthrough Award Level 4 is administered by Defense Health Agency Contracting Activity - DHACA (AMRAA), listed via Grants.gov.

Open the official opportunity page Browse all US R&D funding on GrantField

Programme data is aggregated by GrantField from public sources and may change. Always verify details on the official page before applying.